Origin's business is licensing matched spatial, H&E and clinical tumour data to pharma and AI companies, with contracts from $100K. Yet the homepage never uses the words "license", "dataset" or "pharma", gives no count of samples, patients or cancer types, does not name the spatial platform, and ends in a four-field "Request access" form that does not say what access gives. A translational or AI team that reaches the bottom of the page knows the problem but not what it would be buying. Enable Medicine, which sells to the same teams, leads with scale numbers and names its buyer teams.
First action
Write the cohort table: indication, sample count (current and target), modalities and availability date.
How to measure it
Access requests from pharma, biotech or AI teams naming an indication
- Now
- –
- Target
- 10 a month
- By
- 90 days
Steps
List the cohorts
Indication, samples profiled and planned, modalities, retrospective or prospective, availability.
Computational Biologist, Spatial Transcriptomics 2 days
Decide what to disclose
Exact counts or ranges, and which cohorts are open for exclusivity.
CEO 1 day
Write the spec sheet
One page per cohort: sample fields, QC summary, clinical labels, licence options.
Head of Data Partnerships 3 days
Add the section
"Data catalogue" above the form, plus a /data page linked from the nav.
CTO 2 days
Rename the CTAs
"Request a cohort spec and sample data" in the header and at the form.
CTO 1 hour
Send the spec on request
Auto-reply with the relevant spec sheet and a booking link.
Head of Data Partnerships 1 day
Track
Requests by buyer type and indication, and request-to-NDA rate.
Head of Data Partnerships monthly
Why it works
Add a "Data catalogue" section above the form, and a matching /data page, with: the cancer types and number of samples per cohort (in profiling or available now), what each sample includes (Xenium spatial transcriptomics, aligned H&E whole-slide image, pathologist annotations, clinical labels), retrospective or prospective, how licensing works (evaluation agreement, then licence; exclusivity and early-access options) and a one-page cohort spec sheet to download after the form. Change the form heading to "Request a cohort spec and sample data" and the header CTA to match. The new Head of Data Partnerships then starts from requests that already know what Origin sells.
Data buyers shortlist suppliers on cohort fit and quality before they talk to anyone. Showing indication, size and modality turns a curious visitor into a specific request, and it lets Origin compete on the page with rivals that publish their scale.
Ready to use
ChecklistData catalogue section
[ ] Heading: "Data you can license" [ ] One row per cohort: cancer type, samples (now / target), retrospective or prospective, availability [ ] Per sample: Xenium spatial transcriptomics, aligned H&E whole-slide image, pathologist annotations, clinical labels [ ] QC summary line per cohort [ ] How licensing works: NDA, evaluation agreement, licence; exclusivity and early access [ ] Who it is for: translational, computational biology, AI/ML teams [ ] Form: "Request a cohort spec and sample data" [ ] Auto-reply with the spec sheet
Risks and how to handle them
Small early numbers look weak next to large rivals
Lead with depth per sample (matched spatial, H&E and clinical from one lab) and show the profiling target and date.
Disclosing cohorts helps competitors
Publish indication and size only; keep site, sampling and pricing details for the spec sheet behind the form.
Evidence
- Your websiteHomepage wording (checked November 9, 2026): the words "license", "licensing", "dataset" and "pharma" do not appear; there is no count of samples, patients or cancer types, and the spatial platform is not named; the closing "Request access" form asks only for first name, last name, work email and company, with no text saying what access gives.Source
- HiringHead of Data Partnerships (San Francisco, $200K-$250K, 1-1.5% equity): "This hire will be our first commercial lead." Closes the first data licensing deals with pharma, biotech and AI labs (translational science, computational biology, AI/ML and external innovation teams); runs NDA, data evaluation agreement and licence, with contracts from $100K; packages cohort specs, sample datasets and a data room; prices exclusivity, early access and multi-year terms; feeds buyer needs into what Origin produces next; represents Origin at conferences and on LinkedIn; helps sell AI evaluation benchmarks and RL environments to AI labs.Source
- Y Combinator profileOrigin, "AI and Data for Cancer Therapeutics": Winter 2026 batch, founded 2025, team of 8, San Francisco. The profile says it produces patient-derived cancer datasets for licensing to pharma and AI companies, combining spatial transcriptomics, H&E imaging and clinical labels, runs its own lab and sources samples from biobank and hospital networks. Its YC launch post, "Safer Cell & Gene Therapies with AI", pitched the earlier regulatory DNA work.Source
- Competitor researchEnable Medicine's homepage: "The data to enable better medicine"; it licenses an indexed clinical, spatial, cellular and molecular dataset, speaks to three buyer teams (discovery, translational, data and AI), shows its scale ("20+ disease areas", "200+ clinical sites", "125M+ cells") and sells Tailored Cohorts.Source